TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07527923: First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE1 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 144 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$719,304

Rescue Site Savings

+$473,688

Unlock Full NCT07527923 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07527923 Rescue Dossier →